Mapping the effect of APOE ε4 on gray matter loss in Alzheimer's disease in vivo

Previous studies suggest that in Alzheimer's disease (AD) the Apolipoprotein E (APOE) epsilon4 allele is associated with greater vulnerability of medial temporal lobe structures. However, less is known about its effect on the whole cortical mantle. Here we aimed to identify APOE-related patterns of cortical atrophy in AD using an advanced computational anatomy technique. We studied 15 AD patients carriers (epsilon4+, age: 72+/-10 SD years, MMSE: 20+/-3 SD) and 14 non-carriers (epsilon4-, age: 69+/-9, MMSE: 20+/-5) of the epsilon4 allele and compared them to 29 age-and-sex matched controls (age: 70+/-9, MMSE: 28+/-1). Each subject underwent a clinical evaluation, a neuropsychological battery, and high-resolution MRI. UCLA's cortical pattern matching technique was used to identify regions of local cortical atrophy. epsilon4+ and epsilon4- patients showed similar performance on neuropsychological tests (p>.05, t-test). Diffuse cortical atrophy was detected for both epsilon4+ (p=.0001, permutation test) and epsilon4- patients (p=.0001, permutation test) relative to controls, and overall gray matter loss was about 15% in each patients group. Differences in gray matter loss between carriers and non-carriers mapped to the temporal cortex and right occipital pole (20% greater loss in carriers) and to the posterior cingulate, left orbitofrontal and dorsal fronto-parietal cortex (5-15% greater loss in non-carriers). APOE effect in AD was not significant (p>.74, ANOVA), but a significant APOE by region (temporal vs fronto-parietal cortex) interaction was detected (p=.002, ANOVA), in both early and late-onset patients (p<.05, ANOVA). We conclude that the epsilon4 allele modulates disease phenotype in AD, being associated with a pattern of differential temporal and fronto-parietal vulnerability.

[1]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[2]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[3]  K. Davis,et al.  Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. , 1998, Archives of neurology.

[4]  S. Resnick,et al.  Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype , 2000, Neurology.

[5]  Hiroaki Kazui,et al.  Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer’s disease , 2001, Neurology.

[6]  S. Tsai,et al.  Intelligence and event-related potentials for young female human volunteer apolipoprotein E ε4 and non-ε4 carriers , 2000, Neuroscience Letters.

[7]  H. Soininen,et al.  Apolipoprotein E ε4 Allele Is Associated with Increased Atrophy in Progressive Mild Cognitive Impairment: A Voxel-Based Morphometric Study , 2008, Neurodegenerative Diseases.

[8]  H. Soininen,et al.  Major decrease in the volume of the entorhinal cortex in patients with Alzheimer’s disease carrying the apolipoprotein E ε4 allele , 1998, Journal of neurology, neurosurgery, and psychiatry.

[9]  K. Welsh-Bohmer,et al.  Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. , 1997, Neurology.

[10]  Koenraad Van Leemput,et al.  Automated model-based tissue classification of MR images of the brain , 1999, IEEE Transactions on Medical Imaging.

[11]  Rachelle S. Doody,et al.  Individual Growth Curve Analysis of APOE ε4–Associated Cognitive Decline in Alzheimer Disease , 2005 .

[12]  I. Loy-English,et al.  Gender differences in dementia risk factors. , 2007, Gender medicine.

[13]  Thomas W Teasdale.  The apolipoprotein-ε4 gene: always harmful? , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  A. Fagan,et al.  Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins , 1998, The Journal of Neuroscience.

[15]  K. Marder,et al.  The APOE- (cid:101) 4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 2001 .

[16]  Kiralee M. Hayashi,et al.  Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia , 2004, NeuroImage.

[17]  Charles Ramassamy,et al.  Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent , 1999, Brain Research.

[18]  R. Woods,et al.  Mathematical/computational challenges in creating deformable and probabilistic atlases of the human brain , 2000, Human brain mapping.

[19]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[20]  Koenraad Van Leemput,et al.  Automated model-based bias field correction of MR images of the brain , 1999, IEEE Transactions on Medical Imaging.

[21]  C. DeCarli,et al.  APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. , 1999, Neurology.

[22]  David C. Van Essen,et al.  Application of Information Technology: An Integrated Software Suite for Surface-based Analyses of Cerebral Cortex , 2001, J. Am. Medical Informatics Assoc..

[23]  Paul M. Thompson,et al.  Functional MRI BOLD response to Tower of London performance of first-episode schizophrenia patients using cortical pattern matching , 2005, NeuroImage.

[24]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[25]  Philipp A. Thomann,et al.  Apolipoprotein E Polymorphism and Brain Morphology in Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.

[26]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[27]  E G Tangalos,et al.  Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease , 1998, Annals of neurology.

[28]  K. Davis,et al.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.

[29]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[30]  H J Stam,et al.  Association between apolipoprotein-ε4 and long-term outcome after traumatic brain injury , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[31]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[32]  R. Woods,et al.  Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. , 2007, Cerebral cortex.

[33]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[34]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[35]  C. Caltagirone,et al.  The Mental Deterioration Battery: Normative Data, Diagnostic Reliability and Qualitative Analyses of Cognitive Impairment , 1996 .

[36]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[37]  E G Tangalos,et al.  Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer's disease but not in healthy control subjects , 1998, Neurology.

[38]  R. Woods,et al.  Gender effects on cortical thickness and the influence of scaling , 2006, Human brain mapping.

[39]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[40]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[41]  Alan C. Evans,et al.  Multiple surface identification and matching in magnetic resonance images , 1994, Other Conferences.

[42]  Arto Mannermaa,et al.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele , 1995, Neuroscience Letters.

[43]  E. Mori,et al.  Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. , 2001, Neurology.

[44]  A. Toga,et al.  Mapping sulcal pattern asymmetry and local cortical surface gray matter distribution in vivo: maturation in perisylvian cortices. , 2002, Cerebral cortex.

[45]  E. Renzi,et al.  The token test: A sensitive test to detect receptive disturbances in aphasics. , 1962, Brain : a journal of neurology.

[46]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[47]  David A. Bennett,et al.  Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer’s disease , 2004, Neurobiology of Aging.

[48]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[49]  Marina Boccardi,et al.  The Effect of Apolipoprotein Polymorphism on Brain in Mild Cognitive Impairment: A Voxel-Based Morphometric Study , 2006, Dementia and Geriatric Cognitive Disorders.

[50]  G. Frisoni,et al.  Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. , 1995, Annals of neurology.

[51]  Paul M. Thompson,et al.  Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers , 2008, NeuroImage.

[52]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[53]  Martin Klein,et al.  Cognitive Impairment in Alzheimer’s Disease Is Modified by APOE Genotype , 2007, Dementia and Geriatric Cognitive Disorders.

[54]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Schellenberg,et al.  Dementia and Alzheimer disease incidence: a prospective cohort study. , 2002, Archives of neurology.

[56]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[57]  Christopher Schatschneider,et al.  Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. , 2005, Archives of neurology.

[58]  H. Soininen,et al.  Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease , 1996, Neurology.

[59]  Paul M. Thompson,et al.  A deformable Brodmann area atlas , 2004, 2004 2nd IEEE International Symposium on Biomedical Imaging: Nano to Macro (IEEE Cat No. 04EX821).

[60]  D. V. van Essen,et al.  Windows on the brain: the emerging role of atlases and databases in neuroscience , 2002, Current Opinion in Neurobiology.

[61]  C. K. Liu,et al.  Apolipoprotein E polymorphism and Alzheimer's disease. , 2001, The Kaohsiung journal of medical sciences.

[62]  A D Roses,et al.  The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. , 2000, Biochimica et biophysica acta.

[63]  Daniela Mapelli,et al.  Variability of Trail Making Test, Symbol Digit Test and Line Trait Test in normal people. A normative study taking into account age-dependent decline and sociobiological variables , 2002, Aging clinical and experimental research.

[64]  Charles DeCarli,et al.  APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD , 1999, Neurology.

[65]  A. M. Saunders,et al.  Apolipoprotein E ϵ4 allele and hippocampal volume in twins with normal cognition , 1997, Neurology.

[66]  Richard J. Caselli,et al.  Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates , 2007 .

[67]  L. Thal,et al.  Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease , 2004, Neurology.

[68]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[69]  H. Soininen,et al.  Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes , 1995, Neuroscience.

[70]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[71]  Yaakov Stern,et al.  The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease , 1997, Annals of neurology.

[72]  R. Leahy,et al.  Magnetic Resonance Image Tissue Classification Using a Partial Volume Model , 2001, NeuroImage.

[73]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[74]  A. Smith,et al.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.

[75]  Giovanni B. Frisoni,et al.  Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .

[76]  Daniel Bandy,et al.  Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. , 2007, The American journal of psychiatry.

[77]  Nick C Fox,et al.  Whole-brain atrophy rate in Alzheimer disease , 2008, Neurology.

[78]  Guojun Bu,et al.  Glial Fibrillary Acidic Protein – Apolipoprotein E ( apoE ) Transgenic Mice : Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE 3 and apoE 4 Lipoproteins , 1998 .

[79]  Alan C. Evans,et al.  Enhancement of MR Images Using Registration for Signal Averaging , 1998, Journal of Computer Assisted Tomography.

[80]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[81]  G. Finocchiaro,et al.  Brainstem auditory-evoked responses and clinical picture in a one year follow-up of 18 patients with Friedreich ataxia , 1985, The Italian Journal of Neurological Sciences.

[82]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[83]  S. Tsai,et al.  Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. , 2000, Neuroscience letters.

[84]  M J Bronskill,et al.  Quantitative MR volumetry in Alzheimer's disease , 1997, Neurology.

[85]  I. Tesseur,et al.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. , 2000, The American journal of pathology.

[86]  Giovanni B. Frisoni,et al.  Brain volumes in healthy adults aged 40 years and over: a voxel-based morphometry study , 2005, Aging clinical and experimental research.

[87]  Marcella Laiacona,et al.  Tre test clinici di ricerca e produzione lessicale , 1986 .

[88]  A. Levey,et al.  Apolipoprotein E and age at onset of Alzheimer’s disease in African American patients , 2001, Neurology.

[89]  R. Mahley,et al.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.

[90]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[91]  Minoru Yasuda,et al.  Apolipoprotein E ε4 Allele and Whole Brain Atrophy in Late-Onset Alzheimer's Disease , 1998 .

[92]  H. Soininen,et al.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. , 1995, Neuroscience letters.